Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
De novo PMP2 mutations in families with type 1 Charcot-Marie-Tooth disease.
Pharmacokinetics and pharmacodynamics of MD1003 (high-dose biotin) in the treatment of progressive multiple sclerosis.
NAD⁺ in aging, metabolism, and neurodegeneration.
Information on natalizumab (marketed as Tysabri)
Magnetization transfer imaging in multiple sclerosis treated with alemtuzumab.
How Natalizumab Binds and Antagonizes α4 Integrins.
Immunopathology of multiple sclerosis.
Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients.
Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis.
Cladribine Exposure Results in a Sustained Modulation of the Cytokine Response in Human Peripheral Blood Mononuclear Cells.
Efficacy of fingolimod in patients with highly active relapsing-remitting multiple sclerosis.
Repeated treatment with high dose cyclophosphamide for severe autoimmune diseases.
Cyclophosphamide for multiple sclerosis.
Agreement between physician's recommendation and fitness-to-drive decision in multiple sclerosis.
Mutations affecting segment number and polarity in Drosophila.
Severe haematological complications during treatment with natalizumab.
Monosymptomatic clinically isolated syndrome with sudden sensorineural hearing loss: case report and critical review of the literature.
Therapeutic laquinimod treatment decreases inflammation, initiates axon remyelination, and improves motor deficit in a mouse model of multiple sclerosis.
MARGA: Multispectral Adaptive Region Growing Algorithm for brain extraction on axial MRI.
Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia.
Raltegravir (Isentress) pilot study in relapsing multiple sclerosis (INSPIRE)
Guillain-Barré syndrome in Colombia: where do we stand now?
Dalfampridine Effects Beyond Walking Speed in Multiple Sclerosis.
Deep 3D Convolutional Encoder Networks with Shortcuts for Multiscale Feature Integration Applied to Multiple Sclerosis Lesion Segmentation.
A Multidimensional Computerized Adaptive Short-Form Quality of Life Questionnaire Developed and Validated for Multiple Sclerosis: The MusiQoL-MCAT.
Pages
« first
‹ previous
…
163
164
165
166
167
168
169
170
171
…
next ›
last »